Bevacizumab biosimilar(Zhejiang Teruisi Pharmaceutical)

贝伐珠单抗生物类似药（浙江特瑞思药业）

Report date: 2026/02/01 20:00:10

Base Information

Drug NameBevacizumab biosimilar(Zhejiang Teruisi Pharmaceutical)
Drug Alias Name重组人源化抗VEGF单克隆抗体注射液Recombinant humanized anti-VEGF monoclonal antibody (Zhejiang Teruisi Pharmaceutical)重组人源化抗VEGF单克隆抗体（浙江特瑞思药业）TRS-003
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesZhejiang Teruisi Pharmaceutical Inc
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Teruisi Pharmaceutical Inc
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A